AI Article Synopsis

  • A randomized phase II clinical trial investigated the effectiveness of cediranib, a drug targeting vascular growth factors, when combined with radiation and temozolomide in newly diagnosed glioblastoma patients.
  • Out of 158 participants, 137 were eligible, showing a 6-month progression-free survival (PFS) rate of 46.6% for cediranib versus 24.5% for the placebo, indicating a significant improvement.
  • Although cediranib improved PFS, there was no notable difference in overall survival, and patients receiving cediranib experienced more serious adverse events compared to those on placebo.

Article Abstract

Background: A randomized, phase II, placebo-controlled, and blinded clinical trial (NCT01062425) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, versus placebo in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Methods: Patients with newly diagnosed glioblastoma were randomly assigned 2:1 to receive (1) cediranib (20 mg) in combination with radiation and temozolomide; (2) placebo in combination with radiation and temozolomide. The primary endpoint was 6-month progression-free survival (PFS) based on blinded, independent radiographic assessment of postcontrast T1-weighted and noncontrast T2-weighted MRI brain scans and was tested using a 1-sided test for 2 proportions. Adverse events (AEs) were evaluated per CTCAE version 4.

Results: One hundred and fifty-eight patients were randomized, out of which 9 were ineligible and 12 were not evaluable for the primary endpoint, leaving 137 eligible and evaluable. 6-month PFS was 46.6% in the cediranib arm versus 24.5% in the placebo arm ( = .005). There was no significant difference in overall survival between the 2 arms. There was more grade ≥ 3 AEs in the cediranib arm than in the placebo arm ( = .02).

Conclusions: This study met its primary endpoint of prolongation of 6-month PFS with cediranib in combination with radiation and temozolomide versus placebo in combination with radiation and temozolomide. There was no difference in overall survival between the 2 arms.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660192PMC
http://dx.doi.org/10.1093/noajnl/vdad116DOI Listing

Publication Analysis

Top Keywords

combination radiation
20
radiation temozolomide
20
newly diagnosed
12
placebo combination
12
primary endpoint
12
randomized phase
8
diagnosed glioblastoma
8
versus placebo
8
cediranib combination
8
6-month pfs
8

Similar Publications

The survival prediction analysis and preliminary study of the biological function of YEATS2 in hepatocellular carcinoma.

Cell Oncol (Dordr)

December 2024

Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.

Purpose: Our study aims to develop and validate a novel molecular marker for the prognosis and diagnosis of hepatocellular carcinoma (HCC) MATERIALS & METHODS: We retrospectively analyzed mRNA expression profile and clinicopathological data of HCC patients fetched from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and The International Cancer Genome Consortium (ICGC) datasets. Univariate Cox regression analysis was performed to collect differentially expressed mRNA (DEmRNAs) from HCC and non-tumor tissues, and YEATS2, a prognostic marker, was identified by further analysis. ROC curve, survival analysis and multivariate Cox regression analysis as well as nomograms were used to evaluate the prognosis of this gene.

View Article and Find Full Text PDF

British version of the Iowa test of consonant perception.

JASA Express Lett

December 2024

Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom.

The Iowa Test of Consonant Perception is a single-word closed-set speech-in-noise test with well-balanced phonetic features. The current study aimed to establish a U.K.

View Article and Find Full Text PDF

Platform development toward ultra-intense laser-based simultaneous hard x-ray and MeV neutron multimodal radiography.

Rev Sci Instrum

December 2024

Lawrence Livermore National Laboratory, Livermore, California 94550, USA.

Ultra-intense short-pulse lasers interacting with matter are capable of generating exceptionally bright secondary radiation sources. The short pulse duration (picoseconds to nanoseconds), small source size (sub-mm), and comparable high peak flux to conventional single particle sources make them an attractive source for radiography using a combination of particle species, known as multimodal imaging. Simultaneous x-ray and MeV neutron imaging of multi-material objects can yield unique advantages for material segmentation and identification within the full sample.

View Article and Find Full Text PDF

Chiral Light-Matter Interactions with Thermal Magnetoplasmons in Graphene Nanodisks.

Nano Lett

December 2024

Instituto de Química Física Blas Cabrera (IQF), CSIC, 28006 Madrid, Spain.

We investigate the emergence of self-hybridized thermal magnetoplasmons in doped graphene nanodisks at finite temperatures upon being subjected to an external magnetic field. Using a semianalytical approach, which fully describes the eigenmodes and polarizability of the graphene nanodisks, we show that the hybridization originates from the coupling of transitions between thermally populated Landau levels and localized magnetoplasmon resonances of the nanodisks. Owing to their origin, these modes combine the extraordinary magneto-optical response of graphene with the strong field enhancement of plasmons, making them an ideal tool for achieving strong chiral light-matter interactions, with the additional advantage of being tunable through carrier concentration, magnetic field, and temperature.

View Article and Find Full Text PDF

Purpose: To propose a methodology for integrating the out-of-field and imaging doses to the in-field dose received by radiotherapy (RT) patients. In addition, the impact of considering the total dose in planning and radiation-induced second malignancies (RISM) risk assessment will be evaluated in several scenarios comprising photon and proton treatments.

Methods: The total dose is the voxel-wise sum of the doses from the different radiation sources (accounting for the radiobiological effectiveness) produced during the whole RT chain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: